Platelet Function Is Associated With Dementia Risk in the Framingham Heart Study.
Pubmed ID: 35470685
Pubmed Central ID: PMC9238609
Journal: Journal of the American Heart Association
Publication Date: May 3, 2022
MeSH Terms: Humans, Male, Female, Risk Factors, Longitudinal Studies, Alzheimer Disease, Adenosine Diphosphate, Platelet Aggregation, Platelet Function Tests
Grants: K25 HL151912, P30 AG066512, K23 AG057760
Authors: Johnson AD, Seshadri S, Beiser A, Ramos-Cejudo J, Salinas J, Berger JS, Fillmore NR, Do N, Zheng C, Kovbasyuk Z, Ardekani BA, Bubu OM, Parekh A, Convit A, Betensky RA, Wisniewski TM, Osorio RS, Pomara N
Cite As: Ramos-Cejudo J, Johnson AD, Beiser A, Seshadri S, Salinas J, Berger JS, Fillmore NR, Do N, Zheng C, Kovbasyuk Z, Ardekani BA, Pomara N, Bubu OM, Parekh A, Convit A, Betensky RA, Wisniewski TM, Osorio RS. Platelet Function Is Associated With Dementia Risk in the Framingham Heart Study. J Am Heart Assoc 2022 May 3;11(9):e023918. Epub 2022 Apr 26.
Studies:
Abstract
Background Vascular function is compromised in Alzheimer disease (AD) years before amyloid and tau pathology are detected and a substantial body of work shows abnormal platelet activation states in patients with AD. The aim of our study was to investigate whether platelet function in middle age is independently associated with future risk of AD. Methods and Results We examined associations of baseline platelet function with incident dementia risk in the community-based FHS (Framingham Heart Study) longitudinal cohorts. The association between platelet function and risk of dementia was evaluated using the cumulative incidence function and inverse probability weighted Cox proportional cause-specific hazards regression models, with adjustment for demographic and clinical covariates. Platelet aggregation response was measured by light transmission aggregometry. The final study sample included 1847 FHS participants (average age, 53.0 years; 57.5% women). During follow-up (median, 20.5 years), we observed 154 cases of incident dementia, of which 121 were AD cases. Results from weighted models indicated that platelet aggregation response to adenosine diphosphate 1.0 µmol/L was independently and positively associated with dementia risk, and it was preceded in importance only by age and hypertension. Sensitivity analyses showed associations with the same directionality for participants defined as adenosine diphosphate hyper-responders, as well as the platelet response to 0.1 µmol/L epinephrine. Conclusions Our study shows individuals free of antiplatelet therapy with a higher platelet response are at higher risk of dementia in late life during a 20-year follow-up, reinforcing the role of platelet function in AD risk. This suggests that platelet phenotypes may be associated with the rate of dementia and potentially have prognostic value.